左西替利嗪联合卡介菌多糖核酸治疗慢性荨麻疹疗效观察  

Clinical observation of levocetirizine combined with polysaccharide nucleic acid fraction of bacillus calmette guerin on chronic urticaria

作　　者：刘勤[1] 

机构地区：[1]江苏省海门市人民医院皮肤科,江苏海门226100

出　　处：《中国医药科学》2014年第22期61-63,共3页China Medicine And Pharmacy

摘　　要：目的探讨左西替利嗪联合卡介菌多糖核酸治疗慢性荨麻疹的临床疗效。方法选取我院2012年10月-2013年10月就诊的慢性荨麻疹患者80例,随机分成左西替利嗪联合卡介菌多糖核酸组（治疗组）40例、单用左西替利组（对照1组）20例和单用卡介菌多糖核酸组（对照2组）20例。分别于治疗后1个月和停药后1个月对三组疗效和复发情况进行比较,并对三组用药后的不良反应进行评估。结果治疗后1个月的疗效,治疗组为77.5%,总有效率显著高于两个对照组（P〈0.05）,停药后1个月的复发率,治疗组为11.13%,复发率显著低于两个对照组（P〈0.05）,三组用药后的不良反应差异无统计学意义（P〉0.05）。结论左西替利嗪联合卡介菌多糖核酸治疗慢性荨麻疹疗效确切,复发率低,不良反应轻微,值得临床推广使用。Objective To discuss the clinical efficacy of Levocetirizine combined with BCG-polysaccharide nucleic acid on treatment of chronic urticaria. Methods 80 cases of patients with chronic urticaria in our hospital from 2012 October to 2013 October were selected.They were randomly divided into group of polysaccharide nucleic acid fraction of bacillus calmette guerin（treatment group）40 cases,group of levocetirizine alone（control group 1）20 cases,group of BCG polysaccharide and nucleic acid alone（control groups 2）20 cases.Respectively compares the efficacy and recurrence of the three groups after treatment 1 month and after stopping treatment 1 month,and to assess the effects and adverse after administration of three groups. Results After treatment 1 month,the efficacy of the treatment group was 77.5%,total efficiency was significantly higher than that of two control groups（P〈0.05）,after stopping 1 month treatment,the relapse rate of the treatment group was 11.13%,the recurrence rate was significantly lower than that of two control groups（P0.05）,after treatment there were no significant difference of adverse reactions in three groups（P〉0.05）. Conclusion The effect of levocetirizine combined with polysaccharide nucleic acid fraction of bacillus calmette guerin on treatment of chronic urticaria is exactly with low recurrence rate and few adverse reaction,is worthy of promotion.

关 键 词：左西替利嗪 卡介菌多糖核酸 慢性荨麻疹 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]